Product Images Iclevia

The given text provides information about various studies conducted comparing the use of combination oral contraceptives (COC) with non-use. These studies include NICHD Women's Care Study, French E3N cohort Study, Shanghai Women's Health Study, The Nurses’ Health Study I, and Oxford Family Planning Study. The text also includes statistical measures such as Odds Ratio (OR), Relative Risk (RR), and Hazard Ratio (HR) for some of the studies. Additionally, the text mentions Effect Estimate but it is not clear what it refers to.*

This document provides different methods of contraception for women and the percentage of effectiveness in preventing pregnancy in one year. It shows the range from fewer than 1 pregnancy per 100 women to 85 or more pregnancies per 100 women. The methods include implants, injections, intrauterine devices, sterilization, birth control pills, skin patch, vaginal ring with hormones, condoms, diaphragm, no intercourse during the most fertile days of the monthly cycle, spermicide, withdrawal, and no birth control.*

Not available. The given text seems to be a mixture of random characters, symbols, and words with no clear meaning or context.*

This is a description of a medication called Iclevia™ which is a combination of levonorgestrel and ethinyl estradiol in tablet form. It comes in three extended-cycle wallets, each containing 91 tablets, with 84 white tablets containing 0.15mg levonorgestrel USP and 0.03mg ethinyl estradiol USP and seven green inert tablets. It is used to prevent pregnancy when taken in the prescribed daily doses for 91 consecutive days. It does not protect against sexually transmitted diseases such as HIV. The medication should be stored at room temperature, between 20°C to 25°C. The medication is distributed by Aurobindo Pharma USA, Inc.*

Levonorgestrel is a chemical compound with a molecular weight of 3124 g/mol.*